Neuropace
NPCE
40 hedge funds and large institutions have $150M invested in Neuropace in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 16 reducing their positions, and 6 closing their positions.
0.33% more ownership
Funds ownership: 74.09% → 74.42% (+0.33%)
2% less funds holding
Funds holding: 41 → 40 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
18% less capital invested
Capital invested by funds: $182M → $150M (-$32M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
44% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$6.64M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.94M |
| 3 |
Millennium Management
New York
|
+$2.63M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.55M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$630K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$5.65M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$3.59M |
| 3 |
RCM
Revelation Capital Management
Sausalito,
California
|
-$2.47M |
| 4 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
-$2.03M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$192K |
NPCE Hedge Fund Activity: Q1 2022 in Review
40 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Neuropace (NPCE) for Q1 2022, worth a combined $150M — down 18% from $182M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of NPCE and 5 opened new positions — a net loss of 1 holder — while 16 trimmed existing stakes and 9 added.
The largest buyer was Morgan Stanley, adding an estimated $6.64M. The largest seller was Pictet Asset Management (Switzerland), exiting entirely with an estimated $5.65M sold.
- 40 institutional investors held Neuropace (NPCE) as of Q1 2022, down from 41 in Q4 2021.
- Funds reported $150M of Neuropace stock for Q1 2022, down 18% quarter-over-quarter.
- 5 funds opened new Neuropace positions in Q1 2022 and 6 closed out, a net change of -1 holder.
- The largest Neuropace buyer in Q1 2022 was Morgan Stanley, an estimated $6.64M added.
- The largest Neuropace seller in Q1 2022 was Pictet Asset Management (Switzerland), an estimated $5.65M sold.
Based on aggregated 13F filings for Q1 2022.